Schizophrenia is a chronic mental health disorder that can significantly impact functional abilities and quality of life. Long-acting injectable (LAI) antipsychotics offer proven benefits in improving adherence and reducing relapse risk, yet their potential remains underutilized in clinical practice. Clinicians can benefit from enhancing their understanding of LAIs, particularly in the early phases of schizophrenia, and addressing misconceptions about their use. Concerns about patient receptivity and stigma can also be reframed to encourage more proactive discussions about LAIs as a treatment option. By increasing familiarity with the data supporting LAIs and involving patients and caregivers more effectively in shared decision-making, clinicians can better align treatment plans with individual goals, preferences, and long-term quality-of-life outcomes. This educational activity aims to equip clinicians with the tools to expand the use of LAI therapy and enhance patient engagement strategies to achieve optimal outcomes.
- Provider:Medical Education Resources
- Activity Link: https://mycme.com
- Start Date: 2024-12-10 06:00:00
- End Date: 2024-12-10 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Indivior - Amount: 5000.0 - Is Kind Support: False Source: Teva - Amount: 10000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all